Skip to main content
editorial
. 2024 Aug 12;11(5):1065–1079. doi: 10.1007/s40744-024-00704-y

Table 2.

Immunogenicity of anti-TNF mAbs in psoriatic arthritis

References Product ADAs Impact on serum concentration and clinical response Reduced by methotrexate
[43] Adalimumab 22% Yes Yes
[44]

Adalimumab

Infliximab

29%

21%

Yes Yes
[45] Adalimumab 18% Yes Yes
[46] Golimumab 5% Yes
[47] Infliximab 26% Yes Yes

ADAs anti-drug antibodies, mAbs monoclonal antibodies, TNF tumor necrosis factor